Interstitial Cystitis & Bladder Pain Syndrome

Susan Hoffstetter, PhD, WHNP-BC, FAANP Associate Professor

Saint Louis University School of Medicine Department of Obstetrics, Gynecology & Women's Health Division of Uro-Gynecology St Louis, MO

Disclosures

No disclosures or financial relationships to declare.

Objectives

- 1. Identify symptoms of IC/PBS.
- 2. Describe co-morbidities & risk factors for IC/PBS.
- 3. List evaluation & management strategies for IC/PBS

Definition

"An unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms of more than 6 weeks duration, in the absence of infection or other identifiable causes"

• Hanno. J Urol 2011;185:2162-2170

IC/PBS

- Bladder pain disorder associated with voiding symptomatology & other chronic pain disorders
- Can start with a single symptom & progress to multiple symptoms
- No race or ethnicity differences
- · Occurs across the lifespan
- Men & women affected


Scope of the Problem


- Population based study 2011
 - Random sample
 - 12,752 met criteria to compete questionnaire
 - 2.7% and 6.5 % women met criteria
- Equates to 3.3 to 7.9 million US women over 18 yrs
- Only 9.7% had been given Dx of IC


Berry. J Urol 2011;186:540

Etiology of IC/PBS

- Is it a primary bladder disorder or a secondary phenomena?
 - Hypersensitivity disorder? Common central pathogenesis & pathophysiology
 - Part of a continuum of overactive bladder; Painful vs non painful
 - Known effects on the bladder:
 - Permeability: defect in the bladder epithelium that allows irritating substances in the urine to penetrate into the bladder;
 - · Allergic: Mast cells releasing histamine
 - Breakdown of the glycosaminoglycan layer (GAG)
 - Aberrant neurological signals
 - Immune system attacks the bladder, similar to other autoimmune dx.







Risk Factors

- Female
- Having a chronic pain disorder
- ? Genetic/hereditary
- Only modifiable risk factor
 - caffeine

Co-Morbidities

- Fibromyalgia
- Vulvodynia
- IBS
- Chronic fatigue syndrome
- Depression/anxiety/panic disorder
- Chronic headaches
- Allergies/sensitive skin

Symptoms

- Urinary frequency & urgency; can mimic a UTI
- Supra pubic pain/pressure/discomfort r/t bladder filling. Can be felt in the urethra, vulva, vagina, rectum.
- · Void to avoid or to relieve pain
- · Pain worsens with specific foods or drinks
- Symptoms persist > six week

Diagnostic Tests:

- U/A & culture
- Symptom questionnaire
- Pain evaluation
- Voiding diaries/Frequency/Volume chart
- PVR
- Cytology if + Hx smoking
- Potassium sensitivity test is no longer advised:
 - 26% of IC patients have a negative test, Risks triggering a flare
- Cystoscopy /hydro distention +/- urodynamics when diagnosis unclear

AUA 2014 Guidelines

Self Report Instruments

- · To establish baseline symptoms:
 - O'Leary-Sant Symptom & Problem Questionnaire
 - Pelvic pain & Urgency/frequency (PUF)
- · To evaluate pain:
 - O'Leary-Sant ICSI/ICPI
 - Likert scale
 - Visual Analog scale
 - McGill Pain Questionnaire (short form)

Physical Exam Findings

- Pelvic exam:
 - R/o other conditions
 - Inconsistent findings:
 - Tender anterior vaginal wall/urethra
 - Tender levator muscles
 - Sacroilliac/pubic symphysis tenderness

Differential Diagnosis

- UTI
- Vesical Stones
- Urethral diverticula
- Bladder Cancer
- Effect from previous chemotherapy &/or radiation cystitis
- · Gynecologic condition

Mis-diagnosis?

- Study at SLU Referral Center:
 - 197 patients with dx of recurrent UTI's
- 31.5 % had recurrent UTI's
- 53.3% had IC as sole diagnosis
 - Unpublished data Steele, 2010

Overview of AUA Treatment Guidelines 2014

- Conservative therapies first:
 - Clinical judgment , severity of symptoms & patient preferences
- Combination of simultaneous treatments: reassess; change as needed. If no improvement after multiple treatments, then re-consider the diagnosis
- Avoid use of long term antibiotics & oral glucocorticoids
- Pain management: Limit narcotics, assess throughout, consider multi- disciplinary approach &/ or pain management specialist
- Refer/treat other co-morbidities

Treatment: First Line


- Patient education:
 - Self care/behavioral modification
 - Relaxation/stress management:
 - psychological stress increases pain sensitivity & symptoms
 - meditation, guided imagery, yoga, exercise
- Bladder Retraining:
 - Timed voids
 - Variable results; dependent upon motivation

Urinary Analgesics

- Good for symptom flares:
 - Phenazopyriudium:
 - Orange urine
 - Methylene blue compounds:
 - Contain: Hyoscyamin, (spasms) methenamine (antiseptic), methylene blue (antiseptic), phenyl salicylate (pain)
 - Blue urine

Diet /Fluids

- Allows sense of self control, very individual
- Food diary & lists of irritants:
 - Avoid those foods/fluids that trigger sx
 - IC Diet: avoid caffeine, acid foods, high dose water soluble vitamin supplements
 - Fluids: concentrated urine is irritating
 - Watch temperature: cold/ hot can trigger
 - Gluten free diets, anti-yeast, alkaline diets if finds helpful
- Nutrition supplements



Nutritional Supplements

- Calcium glycerophosphate
 - Take 2 3 tabs or packets with food
 - "Tums for the bladder "– neutralize 98% acid in for juice
 - 3 of 4 pts had decrease in food triggers
- Bologna. Urology 2001;57:119-20
- · Freeze dried aloe vera



Nutritional Supplement

- Dietary supplements target:
 - bladder GAG layer dysfunction:
 - chondroitin sulfate, glucosamine sulfate, sodium hyaluronate
 - bladder inflammation:
 - quercetin, rutin
- Dose: 4 6 tabs / day
- 50% reduction in symptom scores
- Cannot use if seafood or shellfish allergy

Theoharides. Can J Urol 2008;15:4410-4

Treatment: Second Line

- Physical therapy:
 - Manual therapy by pelvic floor specialist
 - Avoid pelvic floor strengthening (Kegel)
- Oral:
 - pentosan polysulfate, hydroxyzine, amitriptyline, cimetidine
- Intra-vesical:
 - Dimethyl Sulfoxide (DMSO)
 - combinations of Heparin, Lidocaine, triamcinolone, bicarbonate

Pentosan Polysulfate

- Only FDA approved treatment
 - Studies usually show 2x placebo rate
 - Improve pain, urgency but not so much nocturia
 - Works better with classic Hunner's ulcer
 - Effectiveness begins within 3 months
 - Usually 300mg as good as 600-900mg
- Severe symptoms may increase to 600 mg
 Higher response rates if you treat early after diagnosis
- 47% of patients with IC were not treated with appropriate therapy in the 1st year after diagnosis

Wu et al Pharmacoeconomics 2006: 55-6

Hydroxyzine

- Anti histamine, decreases CNS activity/sedative
- Rationale mast cells have a pivotal role 25mg increasing to 50 mg q HS Observational studies - > 90% improve

RCT - Hydroxyzine vs. elmiron vs. placebo

- No significant difference
- Underpowered
- 40% response vs. placebo 13%
- Well tolerated with few side effects

Sant. J Urol 2003;170:810-5

Amitripyline

- Tri- cyclic anti- depressant
- 3 RCT's in the IC Network:
 - Dose 10-75
 - 50 mg = 66% response
- 19 months Long-term follow-up 94 pt
 - 64% response at average dose of 55 mg
 - Side Effects:
 - 84% dry mouth
 - 79% and weight gain 59%
 - Risk of sedation/falls in >65 yr
- Pt satisfaction excellent/good 46%

Hertle. Aktulle Urol 2010;Jan 41 Suppl 1:S61

Intravesical Instillations

- "Cocktail for the bladder"
 - Lidocaine (pain)
 - Heparin (replace GAG)
 - Steroid (immune modulator)
 - Bicarbonate (alkaline)
- Weekly for 3-6 weeks
- 50% decrease overall symptoms
- 57% resolution of dyspareunia
- Nocturia decrease by 50%

Dimethyl Sulfoxide Intravesical Instillations

- Penetrates cell membrane
 analgesia, anti-inflammatory, collagenolytic, muscle relaxant
 - FDA approved in 1978
 - Uncontrolled studies
 - Response rates 50 70% 1-2 months
 - May have longer lasting effect for 16 72 months
 - 48% decrease in pain after 1st instillation;
 - Garlic like taste up to 72hrs

Dawson. Cochrane Database Rev 2007;17:CD006113

Other Treatments

- Third- Line:
 - Cystoscopy /hydrodistention under anesthesia
 - Can be used for diagnosis & treatmen
 - Tx of Hunner's ulcer's: fulguration , injection of triamcinolone
- Fourth-Line:
 - onabotulinumtoxinA(Botox0* problem with retention
 - Neuromodulation: Stoller Afferent Nerve Stimulator* or Implantable sacral neurostimuator* (approved for OAB)
- Fifth- Line:
 - Cyclosporine A*
- Sixth- Line: RARE
 - Diversion +/- cystectomy can still have pain
 - Substitution cystoplasty; symptoms/pain can develop in the new bladder
 - * not FDA approved

IC/PBS Costs

- Direct:
 - Annual health care costs 2-2.4 times higher for women with IC/PBS
- Indirect:
 - Lost wages, productivity

Resources for Patients

- IC Association: <u>www.ichelp.org</u>IC Network: <u>www.ic-network.com</u>
 - Support group listings & on line support
 - Blogs/Twitter/You-tube/Facebook
 - Books

IC/PBS Complications

- High rates of pelvic surgery
- Impact of QOL & functioning:
 - Damaging to work life, personal relationships & general health
 - Sleep dysfunction
 - Pain
 - Sexual dysfunction
 - Social functioning difficulties
 - Depression/anxiety/panic attacks

Prognosis

- Chronic pain condition
- Often mis-diagnosed & mis-treated
- Symptoms wax & wane
- Self management strategies are critical
- Urinary analgesics very helpful

References

- Berry S, Elliott, A, Suttorp M et al. Prevalence of Symptoms of Bladder Pain Syndrome/Interstitial Cystitis Among Adult Females in the United States. Urol 2011;186(2):540-544.
- Hanno P, Burks, D, Clemens, J. et al. Urol 2011; Jun: 185(6):2162-2170. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome.
- Hanno P, Burks D Quentin C, et al. 2014 American Urologic Association Guidelines Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome (Amended). AUA.net.
- Steele. A. 2010 Unpublished data. Saint Louis University Urogyn Divison St Louis MO
- Bologna R, Gomelsky A, Lukban J, et al. Urology 2001 57: 119 20.

Questions?

- Theoharides, T, Kempuraj, D, Vakali S. Sant G. . Treatment of refractory interstitial cystitis/painful bladder syndrome with CystoProtek-an oral multi-agent natural supplement.Can J Urol 2008;15(6):4410-4
- Wu e, Birnbaum H, Mareva A et al. Interstitial Cystitis, cost treatment & co-morbidities in an employed population. Pharmacoeconomics 2006; 24 (1): 55-65.
- Dawson T, Jamison J: Intravesical treatments for painful bladder syndrome/interstitial cystitis. Cochrane Database Syst Rev. 2007;17.
- Sant G, Propert K, Hanno P, et al. Treatment of interstitial cystitis. J Urol 2003;170:810-5.
- Hertle L, van Ophoven A. Long-term results of amitriptyline treatment for interstitial cystitis. Aktuelle Urol. 2010 Jan;41 Suppl 1:S61-5.